Lecanemab Frequently Asked Questions

Submitted by Kristine Talley on Sep 8, 2023 - 12:46pm CDT

Resource Type:

Unpublished Document

On July 6, 2023, the Food and Drug Administration (FDA) provided approval for lecanemab (Leqembi) to treat early-stage Alzheimer’s disease. Lecanemab is a medication developed by Eisai and Biogen that may help slow the progression of early stage Alzheimer’s disease. Many people living with dementia, families, and care professionals have questions regarding this news. This document contains frequently asked questions and some answers for a better understanding of what to expect with the FDA approval of lecanemab.

Source: Families and Long-Term Care Project: School of Public Health- University of Minnesota, 2023. https://www.sph.umn.edu/research/projects/ltc/

Author(s):

Families and Long-Term Care Project: School of Public Health- University of Minnesota

Link to Resource:

https://docs.google.com/document/d/1MPC4KoVhOLd_baI-WaNYq-1hsxc92GPF/edit

Subject:

Education & Learning

Patients & Families

Additional Tags (Optional):

lecanemab